Apolipoprotein A-IV concentrations and clinical outcomes in haemodialysis patients with type 2 diabetes mellitus - a post hoc analysis of the 4D Study

Journal of Internal Medicine

Volumn 272, Issue 6, 2012, Pages 592-600

  Kollerits, B ^a   Krane, V ^b   Drechsler, C ^b   Lamina, C ^a   Marz W ^c   Ritz, E ^c   Wanner, C ^b   Kronenberg, F ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

All cause mortality; Apolipoprotein A IV; Haemodialysis; Nutrition; Protein energy wasting

Indexed keywords

APOLIPOPROTEIN A4; ATORVASTATIN; C REACTIVE PROTEIN; CREATININE; PLACEBO; SERUM ALBUMIN;

ADULT; AGED; ARTICLE; BODY MASS; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART INFARCTION; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; POST HOC ANALYSIS; PRIORITY JOURNAL; PROTEIN CALORIE MALNUTRITION; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SUDDEN DEATH;

EID: 84869889876     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2012.02585.x     Document Type: Article

References (32)

1. Utermann G, Beisiegel U. Apolipoprotein A-IV: a protein occurring in human mesenteric lymph chylomicrons and free in plasma. Isolation and quantification. Eur J Biochem 1979; 99: 333-43.
2. Green PHR, Glickman RM, Riley JW, Qinet E. Human apolipoprotein A-IV. Intestinal origin and distribution in plasma. J Clin Invest 1980; 65: 911-9.
3. Ezeh B, Haiman M, Alber HF et al. Plasma distribution of apoA-IV in patients with coronary artery disease and healthy controls. J Lipid Res 2003; 44: 1523-9.
4. Steinmetz A, Barbaras R, Ghalim N, Clavey V, Fruchart J-C, Ailhaud G. Human apolipoprotein A-IV binds to apolipoprotein A-I/A- II receptor sites and promotes cholesterol efflux from adipose cells. J Biol Chem 1990; 265: 7859-63.
5. Stein O, Stein Y, Lefevre M, Roheim PS. The role of apolipoprotein A-IV in reverse cholesterol transport studied with cultured cells and liposomes derived from another analog of phosphatidylcholine. Biochim Biophys Acta 1986; 878: 7-13.
6. Apfelbaum TF, Davidson NO, Glickman RM. Apolipoprotein A-IV synthesis in rat intestine: regulation by dietary triglyceride. Am J Physiol 1987; 252: G662-6.
7. Goldberg IJ, Scheraldi CA, Yacoub LK, Saxena U, Bisgaier CL. Lipoprotein ApoC-II activation of lipoprotein lipase. J Biol Chem 1990; 265: 4266-72.
8. Tso P, Liu M. Apolipoprotein A-IV, food intake, and obesity. Physiol Behav 2004; 83: 631-43.
9. Duverger N, Tremp G, Caillaud JM et al. Protection against atherogenesis in mice mediated by human apolipoprotein A-IV. Science 1996; 273: 966-8.
10. Kronenberg F, Stühlinger M, Trenkwalder E et al. Low apolipoprotein A-IV plasma concentrations in men with coronary artery disease. J Am Coll Cardiol 2000; 36: 751-7.
11. Cohen RD, Castellani LW, Qiao JH, Van Lenten BJ, Lusis AJ, Reue K. Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A-IV. J Clin Invest 1997; 99: 1906-16.
12. Warner MM, Guo J, Zhao Y. The relationship between plasma apolipoprotein A-IV levels and coronary heart disease. Chin Med J (Engl) 2001; 114: 275-9.
13. Wong WM, Hawe E, Li LK et al. Apolipoprotein AIV gene variant S347 is associated with increased risk of coronary heart disease and lower plasma apolipoprotein AIV levels. Circ Res 2003; 92: 969-75.
14. Omori M, Watanabe M, Matsumoto K, Honda H, Hattori H, Akizawa T. Impact of serum apolipoprotein A-IV as a marker of cardiovascular disease in maintenance hemodialysis patients. Ther Apher Dial 2010; 14: 341-8.
15. Luczak M, Formanowicz D, Pawliczak E, Wanic-Kossowska M, Wykretowicz A, Figlerowicz M. Chronic kidney disease-related atherosclerosis - proteomic studies of blood plasma. Proteome Sci 2011; 9: 25.
16. Kronenberg F, König P, Neyer U et al. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 1995; 6: 110-20.
17. Kronenberg F, Kuen E, Ritz E et al. Apolipoprotein A-IV serum concentrations are elevated in mild and moderate renal failure. J Am Soc Nephrol 2002; 13: 461-9.
18. Seishima M, Muto Y. An increased apo A-IV serum concentration of patients with chronic renal failure on hemodialysis. Clin Chim Acta 1987; 167: 303-11.
19. Dieplinger H, Lobentanz E-M, König P et al. Plasma apolipoprotein A-IV metabolism in patients with chronic renal disease. Eur J Clin Invest 1992; 22: 166-74.
20. Lingenhel A, Lhotta K, Neyer U et al. Role of the kidney in the metabolism of apolipoprotein A-IV: influence of the type of proteinuria. J Lipid Res 2006; 47: 2071-9.
21. Boes E, Fliser D, Ritz E et al. Apolipoprotein A-IV predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease Study. J Am Soc Nephrol 2006; 17: 528-36.
22. Foley RN, Murray AM, Li S et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005; 16: 489-95.
23. de Jager DJ, Grootendorst DC, Jager KJ et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 2009; 302: 1782-9.
24. Fouque D, Kalantar-Zadeh K, Kopple J et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 2008; 73: 391-8.
25. Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD. Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis 2003; 42: 864-81.
26. de Mutsert R, Grootendorst DC, Boeschoten EW et al. Subjective global assessment of nutritional status is strongly associated with mortality in chronic dialysis patients. Am J Clin Nutr 2009; 89: 787-93.
27. Wanner C, Krane V, Marz W et al. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney Blood Press Res 2004; 27: 259-66.
28. Wanner C, Krane V, März W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-48.
29. Drechsler C, Grootendorst DC, Pilz S et al. Wasting and sudden cardiac death in hemodialysis patients: a post hoc analysis of 4D (Die Deutsche Diabetes Dialyse Studie). Am J Kidney Dis 2011; 58: 599-607.
30. Kronenberg F, Lobentanz E-M, König P, Utermann G, Dieplinger H. Effect of sample storage on the measurement of lipoprotein(a), apolipoproteins B and A-IV, total and high-density lipoprotein cholesterol and triglycerides. J Lipid Res 1994; 35: 1318-28.
31. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-53.
32. Green D, Roberts PR, New DI, Kalra PA. Sudden cardiac death in hemodialysis patients: an in-depth review. Am J Kidney Dis 2011; 57: 921-9.